BCA
CTXR icon

Bay Colony Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Bay Colony Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,500
Closed -$26.2K – 523
2025
Q2 		$26.2K Buy
16,500
+2,500
+18% +$2.29K ﹤0.01% 464
2025
Q1 		$21.7K Buy
+14,000
New +$33.5K ﹤0.01% 442

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

Bay Colony Advisors's CTXR Position: Q3 2025 in Review

Bay Colony Advisors sold out of Citius Pharmaceuticals (CTXR) in Q3 2025, closing a stake of 16,500 shares — an estimated $26.2K sold.

Bay Colony Advisors first reported a position in CTXR in Q1 2025 and held it in 2 quarters. The position peaked at $26.2K in Q2 2025. 34 funds tracked by Wall St. Rank hold CTXR as of Q3 2025.

  • Bay Colony Advisors reported no remaining Citius Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bay Colony Advisors sold 16,500 Citius Pharmaceuticals shares in Q3 2025, an estimated $26.2K.
  • Bay Colony Advisors first reported a position in Citius Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Bay Colony Advisors's Citius Pharmaceuticals position peaked at $26.2K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2025.

Based on Bay Colony Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.